Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'- dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus

FEBS Letters

Volumn 410, Issue 2-3, 1997, Pages 324-328

  Balzarini, Jan ^a   Kruining, Johannes ^b   Wedgwood, Orson ^c   Pannecouque, Christophe ^a   Aquaro, Stefano ^d   Perno, Carlo Federico ^d   Naesens, Lieve ^a   Witvrouw, Myriam ^a   Heijtink, Rudolf ^b   De Clercq, Erik ^a   McGuigan, Christopher ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

AIDS; HBV; Hepatitis; HIV; Nucleoside analogues; Prodrugs; Reverse transcriptase

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYADENOSINE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION;

ADENOSINE MONOPHOSPHATE; ALANINE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; DIDEOXYADENOSINE; HEPATITIS B VIRUS; HIV; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MOLECULAR STRUCTURE; MOLONEY MURINE SARCOMA VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLONEY MURINE SARCOMA VIRUS; MURINAE; MURINE SARCOMA VIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030786410     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(97)00616-9     Document Type: Article

References (26)

1. Hao Z., Cooney D.A., Hartman N.R., Perno C.F., Fridland A., De Vico A.L., Sarngadharan M.G., Broder S., Johns D.G. Mol. Pharmacol. 34:1988;431-435.
2. Balzarini J., Herdewijn P., De Clercq E. J. Biol. Chem. 264:1989;6127-6133.
3. Balzarini J., Cooney D.A., Dalal M., Kang G.-J., Cupp J.E., De Clercq E., Broder S., Johns D.G. Mol. Pharmacol. 32:1987;798-806.
4. Starnes M.C., Cheng Y.-C. J. Biol. Chem. 262:1987;988-991.
5. Johnson M.A., Ahluwalia G., Connelly M.C., Cooney D.A., Broder S., Johns D.G., Fridland A. J. Biol. Chem. 263:1988;15354-15357.
6. Johnson M.A., Fridland A. Mol. Pharmacol. 36:1989;291-295.
7. Balzarini J., Baba M., Pauwels R., Herdewijn P., De Clercq E. Biochem. Pharmacol. 37:1988;2847-2856.
8. Gray N.M., Marr C.L.P., Penn C.R., Cameron J.M., Bethell R. Biochem. Pharmacol. 50:1995;1043-1051.
9. Eriksson S., Kierdaszuk B., Munch-Petersen B., Öberg B., Johansson N.G. Biochem. Biophys. Res. Commun. 176:1991;586-592.
10. Schinazi R.F., Lloyd R.M. Jr., Nguyen M.-H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., Mellors J.W. Antimicrob. Agents Chemother. 37:1993;875-881.
11. Sastry J.K., Nehete P.N., Khan S., Nowak B.J., Plunkett W., Arlinghaus R.B., Farquhar D. Mol. Pharmacol. 41:1992;441-445.
12. Pompon A., Lefebvre I., Imbach J.-L., Kahn S., Farquhar D. Antiviral Chem. Chemother. 5:1994;91-98.
13. Périgaud C., Gosselin G., Lefebvre I., Girardet J.-L., Benzaria S., Barber I., Imbach J.-L. Bioorg. Med. Chem. Lett. 3:1993;2521-2526.
14. Périgaud C., Aubertin A.-M., Benzaria S., Pelicano H., Girardet J.-L., Maury G., Gosselin G., Kirn A., Imbach J.-L. Biochem. Pharmacol. 48:1994;11-14.
15. Valette G., Pompon A., Girardet J.-L., Cappellacci L., Franchetti P., Grifantini M., La Colla P., Loi A.G., Périgaud C., Gosselin G., Imbach J.-L. J. Med. Chem. 39:1996;1981-1990.
16. Meier, C., Lorey, M., De Clercq, E. and Balzarini, J. (1997) Nucleosides Nucleotides, in press.
17. Naesens, L., Bischofberger, N., Armilli, M., Kim, C. and De Clercq, E. (1997) in: Abstracts of the Tenth International Conference on Antiviral Research, April 6-11, 1997, Atlanta, GA, USA. Antiviral Res., in press.
18. Bischofberger, N., Naesens, L., De Clercq, E., Fridland, A., Srinivas, R.V., Robbins, B.L. Arimilli, M., Cundy, K., Kim, C., Lacy, S., Lee, W. and Shaw, J.-P. (1997) in: Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC, p. 104, no. 214.
19. McGuigan C., Cahard D., Sheeka H.M., De Clercq E., Balzarini J. J. Med. Chem. 39:1996;1748-1753.
20. Balzarini J., Egberink H., Hartmann K., Cahard D., Vahlenkamp T., Thormar H., De Clercq E., McGuigan C. Mol. Pharmacol. 50:1996;1207-1213.
21. Balzarini J., Wedgwood O., Kruining J., Pelemans H., Heijtink R., De Clercq E., McGuigan C. Biochem. Biophys. Res. Commun. 225:1996;363-369.
22. McGuigan C., Wedgwood O.M., De Clercq E., Balzarini J. Bioorg. Med. Chem. Lett. 6:1996;2359-2362.
23. Perno C.-F., Cooney D.A., Gao W.Y., Zang H., Johns D.G., Foli A., Hartman N.R., Calio R., Broder S., Yarchoan R. Blood. 80:1992;995-1003.
24. Heijtink R.A., De Wilde G.A., Kruining J., Berk L., Balzarini J., De Clercq E., Holý A., Schalm S.W. Antiviral Res. 21:1993;141-153.
25. Korba B.E., Milman G. Antiviral Res. 15:1991;217-228.
26. Balzarini J., Karlsson A., Aquaro S., Perno C.-F., Cahard D., Naesens L., De Clercq E., McGuigan C. Proc. Natl. Acad. Sci. USA. 93:1996;7295-7299.